Filing Details

Accession Number:
0001209191-20-026337
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-04-30 16:58:03
Reporting Period:
2020-04-28
Accepted Time:
2020-04-30 16:58:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1708493 Harpoon Therapeutics Inc. HARP Biological Products, (No Disgnostic Substances) (2836) 473458693
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1763592 Holger Wesche C/O Harpoon Therapeutics, Inc.
131 Oyster Point Boulevard, Suite 300
South San Francisco CA 94080
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-04-28 1,250 $0.60 53,919 No 4 M Direct
Common Stock Disposition 2020-04-28 1,250 $14.05 52,669 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2020-04-28 1,250 $0.00 1,250 $0.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
49,756 2027-01-13 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. Represents the weighted average sales price per share. The shares sold at prices ranging from $14.04 to $14.10 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  3. The stock option vested and became exercisable as to 25% of the shares subject to the option on May 24, 2017, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.